{"id":25574,"date":"2022-04-14T08:44:53","date_gmt":"2022-04-14T12:44:53","guid":{"rendered":"http:\/\/www.tasteyourjuice.com\/wordpress\/?p=25574"},"modified":"2022-04-14T08:44:53","modified_gmt":"2022-04-14T12:44:53","slug":"from-the-vta-vta-meets-with-fda-on-synthetic-nicotine","status":"publish","type":"post","link":"https:\/\/www.tasteyourjuice.com\/wordpress\/archives\/25574","title":{"rendered":"FROM THE VTA: VTA Meets with FDA on Synthetic Nicotine"},"content":{"rendered":"

<\/p>\n

VTA Meets with FDA on New Federal Synthetic Nicotine Law<\/u><\/strong><\/div>\n
<\/div>\n
\n
\n

Washington, D.C. – April 13, 2022 – \u00a0<\/strong>After passage of the new law governing synthetic nicotine last month, VTA had to adjust its prior strategy and immediately began working on a strategy to ensure a viable path for companies which are selling products containing synthetic nicotine and which are serious about regulatory compliance. \u00a0A serious strategy for companies intending to file substantive applications would require at least two critical elements.<\/p>\n

First,<\/strong><\/em>\u00a0we knew that it would be critical to engage with FDA to encourage the Agency to take seriously the PMTAs that will be filed.\u00a0 We knew that we had to present to FDA the scientific and public health benefits to the consumer\u00a0and<\/u>\u00a0the Agency of encouraging the development and marketing of products containing synthetic nicotine.\u00a0\u00a0 We knew that we had to counteract the narrative the synthetic nicotine products exist only to circumvent FDA regulation \u2013 a point that has been made by FDA and Members of Congress.\u00a0 We knew that we had to give FDA new reasons to use its enforcement discretion to engage in a full scientific analysis of synthetic nicotine PMTAs.\u00a0 And, we knew that we had to immediately act given the short time frames imposed by the new law.<\/p>\n

To that end,\u00a0last week, VTA\u2019s Board of Directors and members met with the FDA Center for Tobacco Products (CTP).<\/strong>\u00a0 In attendance was a large group of FDA personnel (35+), including senior leaders, representing seven different offices inside CTP dedicated to addressing the issue of synthetic nicotine.\u00a0 Our team included presentations by three Ph.D\u2019s in Organic Chemistry and Physical Analytical Chemistry, enabling us to frame critical scientific and public policy issues that we believe had not previously been presented to or considered by the FDA.\u00a0 We are encouraged by the meeting and are now working on the necessary follow-up.<\/p>\n

Second,<\/strong><\/em>\u00a0we knew that it would be critical to educate Members of Congress on synthetic nicotine who have been fed a negative and narrow narrative that synthetic nicotine products are merely an attempt at circumventing regulation.\u00a0It is clear that Members of Congress know little to nothing about how and\u00a0why<\/em>\u00a0synthetic nicotine was invented or what synthetic nicotine products offer by way of benefits to the public.\u00a0 To that end, VTA\u2019s lobbying team \u2013 which has been working to defend the industry and promote a consistent message on harm reduction since 2015 \u2013 has developed a strategic plan for taking the same message we shared with FDA to Congress and for that we are going to need your help.<\/p>\n

How You Can Help.\u00a0<\/strong>\u00a0As with every other major challenge, we know that a sound and strategic approach can reap benefits but only if approached in a thoughtful manner and if supported with adequate resources.\u00a0 VTA is the trade association that has had a continuous seven-year lobbying presence on Capitol Hill.\u00a0 We have been at the center of every major fight on vaping.\u00a0 While we have not won every fight, we played a pivotal role in every victory and, in so doing, dramatically extended the time our industry had to grow.\u00a0 Here are a few key examples:<\/p>\n<\/div>\n